Last reviewed · How we verify
FluMist/B/Yamagata
FluMist/B/Yamagata is a Live attenuated influenza vaccine (LAIV) Biologic drug developed by MedImmune LLC. It is currently in Phase 3 development for Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations. Also known as: FluMist.
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally.
FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally. Used for Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations.
At a glance
| Generic name | FluMist/B/Yamagata |
|---|---|
| Also known as | FluMist |
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Target | Influenza B virus (Yamagata lineage) surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
FluMist contains live, temperature-sensitive attenuated influenza virus strains that replicate in the cooler upper respiratory tract but cannot replicate in the warmer lower respiratory tract, triggering both mucosal and systemic immune responses. The vaccine strain for Yamagata lineage provides protection against influenza B virus of the Yamagata genetic lineage. This intranasal delivery approach induces local IgA antibodies and cellular immunity in addition to systemic responses.
Approved indications
- Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
- Wheezing
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults (PHASE1)
- Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults (PHASE1)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
- Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine (PHASE3)
- Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers (PHASE2, PHASE3)
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluMist/B/Yamagata CI brief — competitive landscape report
- FluMist/B/Yamagata updates RSS · CI watch RSS
- MedImmune LLC portfolio CI
Frequently asked questions about FluMist/B/Yamagata
What is FluMist/B/Yamagata?
How does FluMist/B/Yamagata work?
What is FluMist/B/Yamagata used for?
Who makes FluMist/B/Yamagata?
Is FluMist/B/Yamagata also known as anything else?
What drug class is FluMist/B/Yamagata in?
What development phase is FluMist/B/Yamagata in?
What are the side effects of FluMist/B/Yamagata?
What does FluMist/B/Yamagata target?
Related
- Drug class: All Live attenuated influenza vaccine (LAIV) drugs
- Target: All drugs targeting Influenza B virus (Yamagata lineage) surface antigens
- Manufacturer: MedImmune LLC — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations
- Also known as: FluMist
- Compare: FluMist/B/Yamagata vs similar drugs
- Pricing: FluMist/B/Yamagata cost, discount & access